A Phase II Study of AS1411 in Renal Cell Carcinoma

Status unconfirmed · Phase 2

Conditions studied: Metastatic Renal Cell Carcinoma

In brief

The aim of this study is to evaluate the efficacy of AS1411 in patients with Metastatic Renal Cell Carcinoma

Key facts

Study ID

NCT00740441

Run by

Antisoma Research

People needed

30

Starts

2008-08-01

Expected to finish

2010-03-01

Last updated by the study team

2009-09-25

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Histologically or cytologically confirmed renal cell carcinoma containing predominant clear cell histology
• Failed or intolerant to 1 or more previous lines of treatments (which must include a Tyrosine Kinase Inhibitor)

You may not qualify if…

• Collecting duct histology
• A history of bleeding disorders or currently taking oral vitamin K antagonise medication
• Unstable brain metastases
• History of prior or concomitant malignancy (except for curatively treated non-melanoma skin cancer or carcinoma in situ of the cervix, or other cancer for which the patient has been disease free for 3 years)

Where it is running

• City of Hope — Duarte, California, United States
• University of California, Davis Cancer Center — Sacramento, California, United States
• University of California San Francisco — San Francisco, California, United States
• St Francis Hospital — Beech Grove, Indiana, United States
• James Graham Brown Cancer Center, University of Louisville — Louisville, Kentucky, United States
• Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute — Boston, Massachusetts, United States
• Medical University of South Carolina — Charleston, South Carolina, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.